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Introduction {#sec001}
============

Endometrial cancer is the sixth most common cancer in women worldwide and the second most common gynecological cancer in Brazil. Its incidence is increasing, in Brazil \[[@pone.0229543.ref001]\] and worldwide, with 382,096 new cases and 89,929 deaths from the disease recorded in 2018 \[[@pone.0229543.ref002]\]. By 2030, the incidence of endometrial cancer is projected to increase by 55% over the number of cases recorded in 2010 in the USA \[[@pone.0229543.ref003]\]. According to the Global Cancer Observatory's 2018 report \[[@pone.0229543.ref004]\], the numbers of new cases and deaths in Brazil were 9,105 and 2,472, respectively, with 15,091 new cases expected by 2040.

This increasing incidence is attributable mainly to cases of type I endometrial cancer caused by excess estrogen unopposed by progesterone. In Brazil, it can be attributed to factors such as increases in life expectancy, decreases in the number of pregnancies, and, especially, the increasing incidence of obesity, a strong risk factor for endometrial cancer \[[@pone.0229543.ref005]\]. Obesity has become a global epidemic, especially among women \[[@pone.0229543.ref006]\]. In 2017, an estimated 51.2% of Brazilian women were found to be overweight \[[@pone.0229543.ref007]\]. The prevalence of obesity among Brazilian women increased from 7.8% in the mid-1970s to 16.9% in 2008 and 24.4% in 2013, and the increase has been the most dramatic among low-income women \[[@pone.0229543.ref008]--[@pone.0229543.ref010]\].

Little information is available regarding the characteristics and outcomes of endometrial cancer in Brazil. The goal of this study was to describe 10 years of experience in the treatment of endometrial cancer at the Instituto do Cancer do Estado de Sao Paulo (ICESP), a public tertiary hospital and university-linked teaching center. The ICESP began these treatment programs in 2008 and receives patients from regions throughout Brazil.

Methods {#sec002}
=======

Institutional approval {#sec003}
----------------------

The protocol for this study was approved by the Scientific Committee of the Faculdade de Medicina da Universidade de Sao Paulo and by the Ethics Committee for Research Projects of the Hospital das Clınicas da Faculdade de Medicina da Universidade de Sao Paulo (Comissao de Ética para Análise de Pesquisa---CAPPesq) and Plataforma Brasil (CAAE06063019400000065). It complies with the ethical precepts proposed by the legislation in force in Brazil R466/2012. The specific informed consent form for this work was waived by the aforementioned Ethics Committee because the study was retrospective, involving data from medical records, with no risks or benefits arising from the results, and with guarantees of full anonymity, including non-public sharing of data.

Study cohort and statistical analysis {#sec004}
-------------------------------------

This retrospective study involved the analysis of data from 703 patients diagnosed with endometrial cancer who were treated at the ICESP between December 2008 and January 2018. Data were imported from the REDCap database. All diagnoses were based on the pathological study of surgical specimens by a team of pathologists at the ICESP Hospital following the guidelines of the College of American Pathologists \[[@pone.0229543.ref011]\]. Other data analyzed were age at diagnosis, ethnicity, body mass index, Karnofsky performance status (KPS), serum CA125, histological type and grade, lymphovascular space invasion (LVSI) (present or absent), tumor size, depth of myometrial infiltration (\<50% or ≥50%), and surgical staging according to the 2009 International Federation of Gynecology and Obstetrics (FIGO) criteria \[[@pone.0229543.ref012]\]. The evaluated patients were divided into two age groups (≤50 years and \>50 years); this cutoff was used because the average age of natural menopause in Brazil is 50 years old \[[@pone.0229543.ref013]\]. Additionally, parameters were compared between patients without functional disabilities (KPS 90 or 100) and patients with an objective loss of functional capacities (KPS 70 or lower). Outcomes were reported according to histological type, surgical FIGO stage, LVSI, and lymph node metastasis. Tumor size was dichotomized in two categories according two different cutoffs for analysis: 2 cm and 4 cm. The concordance between histological biopsy and surgical specimen findings was analyzed. Frequencies and percentages were calculated for qualitative variables, whereas medians and ranges were determined for quantitative variables. Survival curves were constructed by the Kaplan-Meier method and categories of cases were compared by log-rank testing. Multivariate Cox proportional hazard regression modeling with backward stepwise selection of variables was used to analyze other putative factors (beyond FIGO stage and lymph node status) that may be associated with overall survival and disease-free survival. Univariate and multivariate hazard ratios (HRs) were calculated together with 95% confidence intervals (95% CIs). Variables that were found to have *p* values \< 0.10 in the univariate analyses were selected for multivariate model analysis. For all hypothesis testing, a significance level of 5% was applied. The analyses were performed in SPSS v.25 for Windows software.

Results {#sec005}
=======

In the 10-year study period, 703 histologically confirmed cases of endometrial cancer were treated primarily with surgery at our institution. The clinicopathological features of the study sample are shown in [Table 1](#pone.0229543.t001){ref-type="table"}. The following comorbidities were present: morbid obesity (body mass index \> 35 kg/m^2^) (12.7%), diabetes (33.2%), hypertension (62.9%), breast cancer (4.1%), and other cancers (6.1%). Tumor size ranged from 0 cm to 16.5 cm (median, 4.0 cm). Most tumors were low-grade endometrioid malignancies. High-grade tumors included endometrioid G3 and non-endometrioid histological types, with the latter accounting for 19.3% of the cases. The incidence of grade 3 tumors was similar in the first and last 5-year halves of the study period (6.0% *vs*. 8.4%).

10.1371/journal.pone.0229543.t001

###### Characteristics of the study population.

![](pone.0229543.t001){#pone.0229543.t001g}

  Characteristic                           Categories                        N/median^a^   Range      \%
  ---------------------------------------- --------------------------------- ------------- ---------- ------
  **Age**                                                                    63^a^         27--93     
                                           ≤ 50 years                        42                       6.4
                                           \> 50 years                       661                      94
  **Body mass index**                                                        31.1^a^       16--58.9   
  **Race**                                 Caucasian                         550                      78.2
                                           Black                             62                       8.8
                                           Others                            91                       13
  **Histologic type**                      Endometrioid G1/G2                468                      66.5
                                           Endometrioid G3                   99                       14.1
                                           Serous                            93                       13.2
                                           Clear cell                        28                       4
                                           Others                            15                       2.1
  **FIGO (2009) stage**                    IA                                298                      42.4
                                           IB                                151                      21.5
                                           II                                50                       7.1
                                           III                               159                      22.6
                                           IV                                45                       15
  **KPS**                                  ≥90                               533                      75.8
                                           ≤70                               53                       7.5
  **Surgery type**                         Laparotomy                        182                      25.9
                                           Laparoscopic                      480                      68.3
                                           Robotic                           43                       6.1
                                           Vaginal                           2                        0.3
  **Myometrial invasion**                  ≥50%                              343                      48.8
                                           \<50%                             343                      48.8
  **Tumor size**                           \<2 cm                            96                       13.7
                                           2--4 cm                           326                      46.4
                                           \>4 cm                            275                      39.1
  **Lymph node dissection**                                                  551                      78.4
  Pelvic only                              99                                              14.1       
                                           Pelvic and para-aortic            432                      61.5
                                           Para-aortic only                  6                        0.9
  **Median no. lymph nodes recovered**     Pelvic                            15            1--61      
  Para-aortic                              8                                 1--54                    
  **Patients with positive lymph nodes**                                     125                      17.7
                                                                                                      
  **LVSI+**                                                                  208                      29.5
  **Median surgical time (min)**                                             240           57--775    
                                           Laparoscopic                      256           70--681    
                                           Robotic                           320           170--643   
                                           Laparotomy                        180           57--775    
  **Median hospital stay (days)**                                            3             2--57      
  **Adjuvant treatment**                                                     414                      58.9
                                           Chemotherapy                      241                      34.2
                                           External beam radiation therapy   186                      26.4
                                           Brachytherapy                     174                      24.7
  **Recurrence**                                                             93                       13.2
                                           Pelvic only                       16                       2.3
                                           Distant only                      69                       9.8
                                           Pelvic and distant                12                       1.7
  **Death**                                                                  120                      17

The median time between the reporting of the first symptom (abnormal uterine bleeding) at a primary health assistance unit and pathological diagnosis was 9.0 months, and that between diagnosis and treatment at the ICESP was 4.0 months. There was histological concordance between biopsy-based and surgical specimen-based diagnoses in 411/703 cases (58.4%). When tumors were grouped simply as low or high grade, the concordance rate reached 532/703 cases (75.7%).

Before surgery, 583 patients underwent CA125 blood testing, which yielded median values of 21.9 (range, 3--2293) U/mL overall, 15.4 (3--2220) U/mL among patients with stage I tumors, and 37.2 (5.3--2293) U/mL among those with stages III or IV tumors. High and low CA125 level groups were defined by a median cut-off value of 21.9 U/ml. The HR for recurrence was 1.58 (95% CI 1.01--2.49; *p* = 0.047). For overall survival, the HR was 1.86 (95% CI 1.23--2.81; *p* = 0.003).

The number of minimally invasive surgeries increased from 36.4% in the first 2 years of hospital operation (2008 and 2009) to 90.3% in 2017. Lymph node dissection was performed in a total of 551 of the 703 patients (78.4%), systematic pelvic and para-aortic lymphadenectomies were performed in 432 cases (61.5%), pelvic lymphadenectomy alone was performed in 99 cases (14.1%), and para-aortic lymphadenectomy was performed alone in 6 cases (0.9%). The mean numbers (standard deviations) of pelvic and para-aortic lymph nodes dissected were 15 (10.7) and 8 (9.2), respectively. Lymph nodes were positive in 124 cases (17.7%). The median hospital stay was 3 (range, 2--57) days.

The median length of surgery was 240 (range, 57--775) min \[laparoscopic, 256.5 (70--681) min; robotic, 320 (170--643) min; laparotomy, 180 (57--775) min\]. The percentages of patients with high performance status (KPS \> 70) according to surgery type were 92.9% for minimally invasive surgery cases and 86.3% for laparotomy cases. Pelvic and para-aortic lymphadenectomies were performed in 70% of patients who underwent minimally invasive surgery and in 37.9% of those who underwent laparotomy.

Thirty-nine (5.5%) procedures were converted to open surgery, due mainly to technical difficulties encountered during the initial surgeries \[*n* = 24 (61.5%)\], followed by the presence of vascular lesions \[*n* = 9 (23%)\], surgical device malfunctioning \[*n* = 4 (10.3%)\], and anesthesia-related issues \[*n* = 2 (5.1%)\]. In 15 minimally invasive surgeries (2.9%), small laparotomies were performed for surgical specimen removal due to large specimen size.

After surgery, 414 patients (58.9%) received adjuvant treatment, 241 (58.2%) received chemotherapy, 186 (44.9%) received external beam radiation therapy, and 174 (42%) received brachytherapy. Twenty-two patients (3.1%) received neoadjuvant treatment because they had advanced unresectable tumors.

During the follow-up period, recurrence was detected in 93/703 patients (13.2%). The recurrence rate did not differ significantly among patients with stage II and stage III disease (20% and 25.8%, respectively). Local recurrence in the vagina was diagnosed in 21 recurrence cases (22.6%), distributed as follow: patients with initial FIGO stages IA (*n* = 4), IB (*n* = 3), II (*n* = 4), IIIB (*n* = 3), IIIC1 (*n* = 4), IVA (*n* = 1), and IVB (*n* = 2). Seventy percent of patients with local vaginal recurrence had received adjuvant therapy. Inguinal lymph node recurrence was observed in 3 patients (3.2%) with initial stages of IA, IB, and IIIC2. Distant lymph-node metastasis occurred in 28 of the 93 patients with recurrence (30.1%) \[initial FIGO stages IA (*n* = 2), IB (*n* = 4), II (*n* = 6), IIIA (*n* = 1), IIIC1(*n* = 5), IIIC2 (*n* = 4), IVA (*n* = 1), and IVB (*n* = 5)\]. Recurrence was detected in 3.4% and 7.9% of patients with stages IA and IB, disease, respectively. In patients with advanced stage disease, recurrence with \<50% and ≥50% myometrial infiltration was detected in 21.4% and 29.1% of cases, respectively. Recurrence was diagnosed as peritoneal carcinomatosis in 22/93 (23.7%) cases, hepatic metastasis in 7/93 (7.5%) cases, lung metastasis in 22/93 (23.7%) cases, bone metastasis in 5/93 (5.4%) cases, and brain metastasis in 2/93 (2.2%) cases.

Of the 703 patients in the study sample, 97 (13.7%) died during the follow-up period ([Fig 1A](#pone.0229543.g001){ref-type="fig"}). Higher overall and disease-free survival rates were associated with endometrioid histological types ([Fig 1B](#pone.0229543.g001){ref-type="fig"}), FIGO stage I ([Fig 1C](#pone.0229543.g001){ref-type="fig"}), negative lymph nodes ([Fig 2A](#pone.0229543.g002){ref-type="fig"}), and absence of LVSI ([Fig 2B](#pone.0229543.g002){ref-type="fig"}). Disease-free and overall survival did not differ between patients with stage II and stage III disease ([Fig 3](#pone.0229543.g003){ref-type="fig"})

![Overall and disease-free survival for the whole cohort and by histological subtype and FIGO stage.\
(A) Survival rates for entire cohort of patients with endometrial cancer.(B) Survival rates by histological subtype. (C) Survival rates by FIGO stage.](pone.0229543.g001){#pone.0229543.g001}

![Overall and disease-free survival by lymph node status.\
(A) lymph node status. (B)lymph vascular space invasion (LVSI).](pone.0229543.g002){#pone.0229543.g002}

![Overall and disease-free survival in FIGO stage II and III.](pone.0229543.g003){#pone.0229543.g003}

In the univariate analysis, the following parameters were identified as prognostic factors: tumor histology, histological grade, LVSI, tumor size, and myometrial infiltration. All variables had HRs \> 2, except for tumor size ≥ 4 cm for recurrence. In the adjusted analysis, histological grade and LVSI remained independent prognostic factors ([Table 2](#pone.0229543.t002){ref-type="table"}). High histological grade presented the greatest risk for both death (HR = 3.75, *p* \< 0.001) and recurrence (HR = 2.49, *p* = 0.004).

10.1371/journal.pone.0229543.t002

###### Factors associated with overall survival and disease-free survival in patients diagnosed with endometrial cancer.

![](pone.0229543.t002){#pone.0229543.t002g}

  -----------------------------------------------------------------------------------------------------------------
  Parameters associated with overall survival          Univariate                     Multivariate        
  --------------------------------------------- ------ ------------------- ---------- ------------------- ---------
  Histologic type                                      3.1 (2.01--4.6)     \<0.0001                       

  Histologic grade (high *vs*. low)                    4.94 (3.30--7.40)   \<0.0001   3.75 (2.42--5.82)   \<0.001

  LVSI                                                 3.26 (2.21--4.80)   \<0.0001   2.01 (1.32--3.06)   0.001

  Tumor size                                    2 cm   2.46 (1.13--5.32)   0.023                          

                                                4 cm   2.25 (1.43--3.52)   \<0.001                        

  Myometrial invasion                                  3.20 (1.91--5.35)   \<0.0001                       

  **Parameters associated with**\                                                                         
  **disease free survival**                                                                               

  Histologic type                                      3.82 (2.44--5.98)   0.001                          

  Histologic grade                                     5.24 (3.30--8.32)   0.001      2.49 (1.33--4.64)   0.004

  LVSI                                                 5.02 (3.16--7.97)   0.001      3.22 (1.95--5.32)   0.001

  Tumor size                                    2 cm   2.03 (0.88--4.70)   0.099                          

                                                4 cm   1.66 (1.00--2.74)   0.05                           

  Myometrial invasion                                  2.78 (1.81--4.29)   0.001                          
  -----------------------------------------------------------------------------------------------------------------

Discussion {#sec006}
==========

Endometrial cancer occurs mainly in postmenopausal women and is linked to obesity; the ages and body mass index values of our patients reflect this pattern. In addition, the relationship between hypertension and endometrial cancer, which has been recognized for decades \[[@pone.0229543.ref014]--[@pone.0229543.ref017]\], was apparent in this study. In a Danish population study \[[@pone.0229543.ref018]\], 56.6% of patients with endometrial cancer had no comorbidity. Only 12.5% of the patients in our study sample had no comorbidity.

The present study confirmed the importance of classical prognostic factors, namely histological type and grade, LVSI, tumor size, and myometrial invasion.

Histological grade was associated with the greatest risks of death and recurrence in this study. The European Society for Medical Oncology (ESMO)--European Society of Gynaecological Oncology (ESGO)--European Society for Radiotherapy & Oncology (ESTRO) consensus conference statement assigns intermediate risk to grade III endometrioid carcinoma, even in cases of FIGO stage IA tumors without LVSI \[[@pone.0229543.ref019]\]. [Mang](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mang%20C%5BAuthor%5D&cauthor=true&cauthor_uid=28421274) *et al*. \[[@pone.0229543.ref020]\] observed an increase in grade 3 endometrioid carcinoma diagnoses from 18% to 32% between 2006 and 2014 in a sample of 2,611 patients. We observed no such increase.

LVSI is considered almost unanimously to be predictive of a poor prognosis \[[@pone.0229543.ref014]--[@pone.0229543.ref016]\], and this supposition was confirmed in this study in which LVSI increased the risk of recurrence threefold. The ESMO-ESGO-ESTRO consensus assigns intermediate to high risk to early-stage carcinomas \[[@pone.0229543.ref019]\]. This prognostic information becomes very important for decision-making about adjuvant treatment in patients with early-stage disease \[[@pone.0229543.ref021], [@pone.0229543.ref022]\].

LVSI has been recognized as a powerful predictor of lymph node involvement \[[@pone.0229543.ref023]\]. However, the usefulness of this information in deciding whether or not to perform a lymphadenectomy depends on the histology of the surgical specimen, which is limited to frozen section examination during operations. It would be interesting to identify reliable estimates of risk of lymph node involvement based on biopsy findings. In a previous study with 47 consecutive patients who had complete surgical staging, we found LVSI in 63.4% of cases, and L1CAM positivity in 17% of the cases. All L1CAM-positive cases had LVSI, suggesting a potential role of this molecule at the time of diagnostic biopsy, particularly in identifying patients in whom lymphadenectomy is crucial \[[@pone.0229543.ref024]\].

Tumors were larger in our study population than in patients with endometrial carcinoma in studies from developed countries. In a series of 703 cases reported by AlHilli *et al*. \[[@pone.0229543.ref025]\], 29.8% of tumors were ≤2 cm in size whereas in our cohort only 13.7% of tumors were ≤2 cm. This difference may be attributable to delayed care and resolution of cases in our study population. The intervals between initial symptom reporting, diagnosis, and treatment support this assumption. Delayed diagnosis and treatment initiation are strongly related to the prognosis of patients with endometrial carcinoma, and longer wait times from diagnosis to surgery have a negative impact on survival \[[@pone.0229543.ref026]\]. Outpatient endometrial biopsy is not widespread in Brazil; most gynecologists prefer to refer patients with abnormal uterine bleeding to hysteroscopy services. In our opinion, this practice may be a major factor contributing to delayed diagnosis. We have thus been encouraging our colleagues to spread the practice of outpatient endometrial biopsy.

The type of surgery used to treat endometrial carcinomas changed considerably at our institution over the study period, with a marked increase in the performance of minimally invasive (traditional laparoscopic and robotic) surgeries \[[@pone.0229543.ref027]--[@pone.0229543.ref029]\]. Currently, laparoscopy is the treatment of choice, employed in \>90% of cases. Robotic surgery is performed primarily within the bounds of research projects due to its high cost in Brazil, especially in a public service setting \[[@pone.0229543.ref027]\]. Complete surgical staging with pelvic and para-aortic lymph node dissection was performed in most of our patients, but lymph nodes were positive in a relatively small percentage of cases. Other prognostic factors, such as molecular profile factors, may aid in the identification of patients at low risk of lymph node involvement who may be well-suited for potential treatment in community hospitals.

The rate of local recurrence among patients with early (stage I or II) disease was about 1.2% in our sample, and most patients with vaginal recurrence had received adjuvant radiotherapy. Recently, Francis *et al*. \[[@pone.0229543.ref030]\] reported a relatively high vaginal recurrence rate (3.7%), probably because only 25% of their patients received adjuvant radiotherapy. An unexpected finding of our study was that patients with stage II and stage III tumors had similar recurrence rates as well as similar disease-free (*p* = 0.087) and overall survival (*p* = 0.368) outcomes. It is expected that prognoses would be better for patients with tumors invading only the stroma of the cervix, with no extension beyond the uterus (stage II), than for those with invasion of the uterine serosa, parametrium, or lymph nodes (stage III). For endometrial cancer, FIGO stage II does not differentiate between tumors originating in the body of the uterus and extending contiguously to the cervix from those originating in the lower uterine segment and extending to the cervix, despite the quite different behaviors of these two disease presentations. Lymphatic drainage differs between the lower and upper segments of the uterus. Lower uterine segment involvement (LUSI) correlates with more LVSI and other poor prognostic factors, such as lymph node metastasis, uterine serosal involvement, and deep myometrial invasion \[[@pone.0229543.ref031]\]. Cokmez and Yilmaz reported LUSI in 49 (19.4%) of 253 cases of endometrioid endometrial carcinoma \[[@pone.0229543.ref032]\]. Patients with LUSI presented more LVSI (36.7% *vs*. 11.8%, *p* \< 0.05) and more lymph node metastasis (18.4% *vs*. 4.9%, *p* \< 0.05) than patients without LUSI \[[@pone.0229543.ref032]\]. Pathologists should report LUSI because this information could be used as a staging criterion for endometrial carcinoma in the future.

This study has several strengths. First, it presents the largest case series of Brazilian patients with endometrial cancer from a single tertiary institution with a uniform surgical and pathology team, following rigid guidelines, reported thus far. The tumors in all of the cases were submitted to systematic surgical staging. Additionally, the patients underwent predominantly minimally invasive procedures, and every patient in the series had a well-documented outcome. Notably, our finding of similar prognoses among stages II and III cases should prompt an important discussion about the significance of cervical involvement. Furthermore, our data raise questions about the importance of differentiating between tumors originating in the lower uterine segment from those originating in the uterine body or fundus. That is, it should be considered whether lower uterine segment carcinomas and endometrial carcinomas should be treated as distinct entities.

Our study had some weaknesses. First, there may be biases in our data associated with the study being retrospective. Secondly, the study period encompassed a relatively long primary treatment period (10 years), during which there was a learning curve for minimally invasive surgery, a reduction in the number of open operations, and changes in the standards of care for adjuvant treatments. Lastly, we focused on the analysis of classical variables, without examining molecular factors. Notwithstanding, the large number of cases subjected to uniform analyses in this study allowed us to delineate the presentation of endometrial cancer in a Brazilian patient population and our results may thus provide information that is useful for health policy development in Brazil and in other countries with characteristics similar to Brazil.

Conclusion {#sec007}
==========

Our study confirms the importance of the classical prognostic factors of histological type and LVSI as strong predictors of poor prognosis in patients diagnosed with endometrial cancer. The present findings of similar disease-free and overall survival outcomes between patients with stage II versus stage III disease indicate that the prognostic value of cervical involvement and tumor origination in the lower uterine segment should be explored further. Although most of the cases in this series had early-stage diagnoses, we observed tumors that were larger in size than are commonly observed in studies performed in more developed countries, presumably due to later diagnosis. The findings of this study can be used to guide public policies aimed at improving the timeliness of endometrial cancer diagnosis and treatment in Brazil and in other low and medium developing countries.

Supporting information {#sec008}
======================
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Click here for additional data file.
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Reviewer \#1: Im very appreciated to have reviewing this manuscript. The purpose of retrospective study is analyzed and evaluated the characteristics and prognostic factors of 703 patients with endometrial cancer treated at a single center over ten years, The data showed in this study was interesting and meaningful, but I have some comments and suggestions:

1\. Firstly, please submit as a regular and standardized format of Plos One, it will help for the whole system and structure of this article;

2\. Weaknesses are retrospective study and no something new point. It is better to describe more reasons to accept the authors\' hypothesis.

3\. In Table 1, the what is the foundation of your claim to stratified "Age" as 53 years, and "KPS stratified as 70 and 90", and so on in the Table1. The methods are not mention in the statistical analysis.

4\. This study is a valuable study but I think it is somewhat insufficient to publish in this journal.

Reviewer \#2: In this study, the authors analyze the characteristics, prognostic factors and outcomes of patients with endometrial cancer treated at a single tertiary Brazilian institution over a 10-year period. It was finally concluded that histological type and LVSI were strong prognostic predictors in this population. This study reports the characteristics and outcomes of endometrial cancer in a large population from a single institution. Its findings may be used to guide public policies of endometrial cancer in Brazil.

In my opinion, the methodology of this manuscript is correct and the statistical is appropriate. However, what is the innovation of the study? The prognostic factors related to endometrial cancer mainly include clinical stage, histological type, LN metastatic status, LVSI, etc. Why is the conclusion of this study only related to histological type and LVSI? It is recommended that the author give interpretation and discussion and highlight the novelty of the study.

Moreover, the manuscript needs substantial revision and improvement in English writing which are critical to the understanding of the research. Here are some comments；

1\) "The disease-free and overall survival did not differ significantly between patients with stages II and III disease."

Please give the P values in each of the situation.

2\) "Tumor size ranged from 0 to 16.5 cm (median 4cm Most tumors were endometrioid low grade."

There missed a ")" after "4cm".

3\) "Before surgery, 583 patients underwent CA125 testing. The median values were 21.9 (range 3--2293) U/mL overall, 15.4 (3--2220) U/mL among patients with stage I tumors, and 37.2 (5.3--2293) U/mL among those with stages III and IV tumors."

Please analysis whether there is a survival difference between high CA125 group and low CA125 group (the author can use 21.9U/ml as a cutoff value).

4\) Please describe the method of calculating the adjusted hazard ratios (HR).

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229543.r002
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R.: We thank the editor and the reviewers for the careful analysis of our work. Please find below our answers and we are available for further clarification.

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

R.: All the format alterations according PLoS style were done and we chose to highlight (in yellow) only text modifications and not formatting changes.

2\. Thank you for including your ethics statement in the manuscript: \'This retrospective study (institutional review board approval no. 457913--2018) involved the analysis of data from 703 patients diagnosed with endometrial cancer attended at the ICESP between December 2008 and January 2018.\'

a\) Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study and confirm that your named institutional review board or ethics committee specifically approved this study.

b\) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

R.: We included the statement in the Methods statement, highlighted in yellow.

4\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.3802/jgo.2018.29.e100>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

R.: Sorry, but we couldn't identify the overlapping text. If you can help us by pointing out the sections with a problem more accurately, we appreciate it.

Additional Editor Comments (if provided):

The manuscript might be significant for public health strategy in Brazil. However, the analysis of prognostic factors in Table 2 only by a univariate analysis seems inadequate. Please consider a multivariate analysis for all the factors before you draw a scientific conclusion. Also, there is no limitation in this study mentioned.Also, please provide a paragraph of the potential limitations in the present analysis.

R.: Thanks for the comments. The multivariate analysis was done and it is in 4th and 5th columns of Table 2. The description of the statistical method is highlighted in blue in the Method section. Potential limitations as strengths were highlighted in green, in the Discussion section.

 

Reviewers\' comments:

Reviewer \#1: Im very appreciated to have reviewing this manuscript. The purpose of retrospective study is analyzed and evaluated the characteristics and prognostic factors of 703 patients with endometrial cancer treated at a single center over ten years, The data showed in this study was interesting and meaningful, but I have some comments and suggestions:

R.: Thanks for the comments and useful suggestions.

1\. Firstly, please submit as a regular and standardized format of Plos One, it will help for the whole system and structure of this article;

R.: All the format alterations according PLoS style were done. We chose to highlight (in yellow) only text modifications and not formatting changes.

2\. Weaknesses are retrospective study and no something new point. It is better to describe more reasons to accept the authors\' hypothesis.

R.: Thanks for the comment. We agree and we have provided a more detailed description of the strengths and weaknesses in the discussion section (highlighted in green).

3\. In Table 1, the what is the foundation of your claim to stratified "Age" as 53 years, and "KPS stratified as 70 and 90", and so on in the Table1. The methods are not mention in the statistical analysis.

R.: The 50y cut-off was selected because is the average age of natural menopause in Brazil, so we could have an idea of premenopausal incidence. We explained better in the Method section.

The KPS 90 or 100 was compared to 70 or less because we want to identify the proportion of patients without disabilities vs. those with significant symptoms, excluding the cases doubtful. We justified in the Method section (highlighted in green).

4\. This study is a valuable study but I think it is somewhat insufficient to publish in this journal.

R.: We hope that after the changes, mostly motivated by your comments, the paper become more attractive.

Reviewer \#2:

In this study, the authors analyze the characteristics, prognostic factors and outcomes of patients with endometrial cancer treated at a single tertiary Brazilian institution over a 10-year period. It was finally concluded that histological type and LVSI were strong prognostic predictors in this population. This study reports the characteristics and outcomes of endometrial cancer in a large population from a single institution. Its findings may be used to guide public policies of endometrial cancer in Brazil.

In my opinion, the methodology of this manuscript is correct and the statistical is appropriate. However, what is the innovation of the study? The prognostic factors related to endometrial cancer mainly include clinical stage, histological type, LN metastatic status, LVSI, etc. Why is the conclusion of this study only related to histological type and LVSI? It is recommended that the author give interpretation and discussion and highlight the novelty of the study.

R.: Thanks for the comments. We provided some changes, particularly in discussion, including weaknesses and strengths. Furthermore, we emphasized our finding related to similar prognosis of stages II and III (highlighted in green in the Discussion section and in the abstract). Besides, this study exposes an important problem, common to less developed countries, which is late diagnosis and encourages a changing in the approach of diagnosis (office biopsy instead of hysteroscopy).

Moreover, the manuscript needs substantial revision and improvement in English writing which are critical to the understanding of the research.

R.: We sent this version of the manuscript to revision by a professional edition service (Write Science Right; see certificate of edit) and they made a lot of changes. These changes are highlighted in pink. Please, let me know if it's OK.

Here are some comments；

R.: Thanks for observations.

1\) "The disease-free and overall survival did not differ significantly between patients with stages II and III disease."

Please give the P values in each of the situation.

R.: Done. Highlighted in blue.

2\) "Tumor size ranged from 0 to 16.5 cm (median 4cm Most tumors were endometrioid low grade."

There missed a ")" after "4cm".

R.: Thanks! Highlighted in blue

3\) "Before surgery, 583 patients underwent CA125 testing. The median values were 21.9 (range 3--2293) U/mL overall, 15.4 (3--2220) U/mL among patients with stage I tumors, and 37.2 (5.3--2293) U/mL among those with stages III and IV tumors."

Please analysis whether there is a survival difference between high CA125 group and low CA125 group (the author can use 21.9U/ml as a cutoff value).

R.: Thanks for the suggestion. We included HR for DFS and OS using the cut-off of median (21.9U/ml) (highlighted in blue).

4\) Please describe the method of calculating the adjusted hazard ratios (HR).

R.: The method was described in the inserted text highlighted in blue in the last paragraph of the Study cohort and statistical analysis
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Dear Dr. Anton,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All the questions were answered and revised adequately.

Reviewers\' comments:
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Dear Dr. Anton:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Chia-Hsun Hsieh

Academic Editor

PLOS ONE
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